Abstract
The deregulated proteolysis is associated with various diseases in humans. Proteases are commonly regarded as the therapeutic targets. Almost one-third of all proteolytic enzymes in humans are serine proteases. This work provides a brief characteristic of the proteinaceous natural inhibitors, mostly of serine proteases. The examples of some classical and recently identified canonical and noncanonical inhibitors as well as serpins are described. Their actual and potential therapeutic applications are discussed.
Keywords: Serine proteases, canonical, non-canonical inhibitors, serpins.
Current Pharmaceutical Design
Title:Natural Proteinaceous Inhibitors of Serine Proteases
Volume: 19 Issue: 6
Author(s): Dawid Debowski
Affiliation:
Keywords: Serine proteases, canonical, non-canonical inhibitors, serpins.
Abstract: The deregulated proteolysis is associated with various diseases in humans. Proteases are commonly regarded as the therapeutic targets. Almost one-third of all proteolytic enzymes in humans are serine proteases. This work provides a brief characteristic of the proteinaceous natural inhibitors, mostly of serine proteases. The examples of some classical and recently identified canonical and noncanonical inhibitors as well as serpins are described. Their actual and potential therapeutic applications are discussed.
Export Options
About this article
Cite this article as:
Debowski Dawid, Natural Proteinaceous Inhibitors of Serine Proteases, Current Pharmaceutical Design 2013; 19 (6) . https://dx.doi.org/10.2174/138161281906140714121225
DOI https://dx.doi.org/10.2174/138161281906140714121225 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Isolated Unilateral Tongue Oedema: The Adverse Effect of Angiotensin Converting Enzyme Inhibitors
Current Drug Safety Challenges in the Management of Severe Asthma: Role of Current and Future Therapies
Current Pharmaceutical Design Allergy After Inhalation and Ingestion of Cereals Involve Different Allergens in Allergic and Celiac Disease
Recent Patents on Inflammation & Allergy Drug Discovery Aliskiren: A Novel Renin Inhibitor for Hypertension
Current Drug Therapy Review of Newer Anticoagulants and Anti-platelet Agents in Acute Coronary Syndrome and Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Topical Imiquimod: Mechanism of Action and Clinical Applications
Mini-Reviews in Medicinal Chemistry Editorial (Current and Emerging Pharmacological Therapies of Ischaemic Stroke)
CNS & Neurological Disorders - Drug Targets The Indian Pediatric HIV Epidemic: A Systematic Review
Current HIV Research Mast Cell Disorders In Drug Hypersensitivity
Current Pharmaceutical Design Pharmacological Effects of RAAS Blockade in Ischemic Nephropathy
Current Drug Metabolism Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Designing Peptidomimetics
Current Topics in Medicinal Chemistry New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design The Renin Inhibitor Aliskiren as Novel Treatment for Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Current Pharmaceutical Design Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Occupational Allergy in Healthcare Workers
Recent Patents on Inflammation & Allergy Drug Discovery